HomeCompareSCU vs MRK

SCU vs MRK: Dividend Comparison 2026

SCU yields 3.14% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.6K in total portfolio value
10 years
SCU
SCU
● Live price
3.14%
Share price
$12.72
Annual div
$0.40
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full SCU calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SCU vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCUMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCU + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCU pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCU
Annual income on $10K today (after 15% tax)
$267.30/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,328.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCU + MRK for your $10,000?

SCU: 50%MRK: 50%
100% MRK50/50100% SCU
Portfolio after 10yr
$38.5K
Annual income
$4,899.23/yr
Blended yield
12.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SCU
No analyst data
Altman Z
0.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCU buys
0
MRK buys
0
No recent congressional trades found for SCU or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCUMRK
Forward yield3.14%2.76%
Annual dividend / share$0.40$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$20.2K$56.8K
Annual income after 10y$0.32$9,798.13
Total dividends collected$317.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCU vs MRK ($10,000, DRIP)

YearSCU PortfolioSCU Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,857$157.23$11,206$366.19$349.00MRK
2$11,697$79.77$12,650$502.35$953.00MRK
3$12,556$40.16$14,407$694.19$1.9KMRK
4$13,455$20.14$16,585$967.82$3.1KMRK
5$14,407$10.09$19,342$1,363.89$4.9KMRK
6$15,420$5.05$22,913$1,947.19$7.5KMRK
7$16,502$2.52$27,662$2,823.89$11.2KMRK
8$17,659$1.26$34,159$4,173.35$16.5KMRK
9$18,896$0.63$43,337$6,308.80$24.4KMRK
10$20,219$0.32$56,776$9,798.13$36.6KMRK

SCU vs MRK: Complete Analysis 2026

SCUStock

Sculptor Capital Management, Inc. is a publicly owned hedge fund sponsor. The firm provides investment advisory services to its clients. It primarily caters to institutional investors, which include pension funds, fund-of-funds, foundations and endowments, corporations and other institutions, private banks and family offices. The firm also manages separate client-focused equity, fixed income, and real estate separate accounts. It also manages commingled funds and specialized products. The firm invests in equity, fixed income and real estate markets across the world. It employs quantitative and qualitative analysis to make its investments through a combination of fundamental bottom-up research, a high degree of flexibility, and integrated risk management. For its multi-strategy portfolios, the firm employs strategies like convertible and derivative arbitrage, corporate credit, long/short equity special situations, buyout investments, merger arbitrage, private investments, and structured credit. It also invests in real estate and traditional real estate assets including multifamily, office, hotel and retail, loans, portfolio acquisitions, loan pools, operating companies, structured debt products, public securities, and non-traditional real estate assets including gaming, distressed land and residential, cell towers, parking, golf, debt and senior housing. For private equity investments, it considers investments in a variety of special situations that seek to realize value through strategic sales or initial public offerings. The firm was previously known as Och-Ziff Capital Management Group Inc. Sculptor Capital Management, Inc. was founded in 1994 and is based New York, New York.

Full SCU Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SCU vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCU vs SCHDSCU vs JEPISCU vs OSCU vs KOSCU vs MAINSCU vs JNJSCU vs ABBVSCU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.